I
Iradj Sobhani
Researcher at University of Paris
Publications - 138
Citations - 6427
Iradj Sobhani is an academic researcher from University of Paris. The author has contributed to research in topics: Cancer & Colorectal cancer. The author has an hindex of 39, co-authored 128 publications receiving 5403 citations. Previous affiliations of Iradj Sobhani include French Institute of Health and Medical Research & Paris Diderot University.
Papers
More filters
Journal ArticleDOI
Patients' comorbidities reduce the clinical value of emergency colonoscopy: results of a retrospective cohort study.
Cristiano Cremone,Anouk Esch,Charlotte Gagniere,Alessandro Fugazza,Faria Mesli,Michael J. Levy,Aurelien Amiot,Alexis Laurent,Yann Lebaleur,Francois Hemery,Nicolas De’Angelis,Francesco Brunetti,Iradj Sobhani +12 more
TL;DR: The highest advantage was observed in patients with red blood hemorrhage, diarrhea, and colon distension when symptoms were not associated with multiorgane failure, heart transplantation, or septic shock, and patients experience a higher rate of early mortality regardless of whether they undergo urgent colon surgery.
Journal ArticleDOI
Comparison of squamous cell carcinoma of the canal anal (SCCA) prognosis in patients infected or not by human immunodeficiency virus (HIV)
Nicolas Mathieu,Thomas Aparicio,Françoise Roudot-Thoraval,N. Lemarchand,P. Bauer,Christophe Hennequin,Emmanuel Mitry,C. Romelaer,Laurent Abramowitz,Iradj Sobhani +9 more
TL;DR: Clinical outcome and pattern of care of patients recently treated for SCCA according to HIV status were compared to reveal a worst prognosis in HIV+ than in HIV- patients.
Journal ArticleDOI
Obesity and Cancer: yin/yan Effects of Nutrition
Iradj Sobhani,Jeand David Zeitoun,Elise Chanteloup,Antoine Charachon,Michael J. Levy,Jean Charles Delchier +5 more
TL;DR: Exercise, obesity and anti tumor immune response are considered when designing colon cancer screening protocols and insulin resistance is important in the pathogenesis of CRC.
Journal Article
Helicobacter pylori et pathologie gastroduodénale. Première Partie: Physiopathologie et méthodes de diagnostic.
Journal ArticleDOI
LBA46 Bevacizumab (B) plus FOLFIRI after failure of platinum-etoposide in patients (pts) with advanced neuroendocrine carcinoma (NEC): The PRODIGE 41-BEVANEC randomized phase II study
Thomas A. Walter,Astrid Lièvre,Romain Coriat,David Malka,Farid El Hajbi,Frédéric Di Fiore,O. Hentic Dhome,Vincent Hautefeuille,Guillaume Roquin,Marine Perrier,Laetitia Dahan,V. Granger,Iradj Sobhani,Laurent Mineur,Patricia Niccoli,Eric Assenat,Karine Le Malicot,Côme Lepage,Catherine Lombard Bohas +18 more
TL;DR: In this article , the authors evaluated the effect of Folfiri-B vs FOLFIRI on the 6-month overall survival (OS) of colorectal cancer patients.